Dec 17, 2018 Vedanta Biosciences Initiates Phase 2 Study for Lead Rationally-Defined Bacterial Consortium Product Candidate, VE303
Dec 10, 2018 Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
Nov 27, 2018 Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for Inflammatory Bowel Disease
Nov 6, 2018 Vedanta Biosciences Announces Preclinical Data on Microbiome-Derived Immuno-Oncology Candidate
Oct 4, 2018 Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303
Jul 10, 2018 Vedanta Biosciences Receives Award from the Crohn’s & Colitis Foundation to Advance a Microbiome-Derived Therapeutic Program for Interception and Treatment of Inflammatory Bowel Disease
Dec 13, 2017 Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia